All In Biotech

Drug Trial Radar · NCT07453602

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

A Phase 1a/1b, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 in Healthy Volunteers and Subjects With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Arcutis Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.

Conditions

  • Atopic Dermatitis (AD)
  • Eczema

Interventions

  • ARQ-234Biological

    ARQ-234 subcutaneous injectable solution

  • PlaceboDrug

    Placebo subcutaneous injectable solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants who experience an adverse event (AE) or serious adverse event (SAE)Time frame: From screening to the last follow up visit for each study part (Part A: 16 weeks, Part B: 30 weeks, Part C: 30 weeks)
  2. Percent change from Baseline in the Eczema Area and Severity Index (EASI) score, a validated measure of disease severity in atopic dermatitis.Time frame: From Baseline to Week 16

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site 112

    Miami, Florida · Recruiting

  • Clinical Site 110

    Miami, Florida · Recruiting

  • Clinical Site 106

    Plainfield, Indiana · Recruiting

  • Clinical Site 101

    Fair Lawn, New Jersey · Recruiting

  • Clinical Site 102

    College Station, Texas · Recruiting

  • Clinical Site 104

    San Antonio, Texas · Recruiting

  • Clinical Site 109

    South Jordan, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.